Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1999 1
2000 6
2001 1
2002 1
2003 2
2004 1
2005 7
2006 7
2007 11
2008 6
2009 6
2010 6
2011 7
2012 22
2013 21
2014 20
2015 25
2016 30
2017 38
2018 21
2019 11
2020 17
2021 26
2022 11
Text availability
Article attribute
Article type
Publication date

Search Results

252 results
Results by year
Filters applied: . Clear all
Page 1
ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis.
Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, Clanet M, Comi G, Derfuss T, Fazekas F, Hartung HP, Havrdova E, Hemmer B, Kappos L, Liblau R, Lubetzki C, Marcus E, Miller DH, Olsson T, Pilling S, Selmaj K, Siva A, Sorensen PS, Sormani MP, Thalheim C, Wiendl H, Zipp F. Montalban X, et al. Among authors: havrdova e. Mult Scler. 2018 Feb;24(2):96-120. doi: 10.1177/1352458517751049. Epub 2018 Jan 20. Mult Scler. 2018. PMID: 29353550
Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial.
Kappos L, Fox RJ, Burcklen M, Freedman MS, Havrdová EK, Hennessy B, Hohlfeld R, Lublin F, Montalban X, Pozzilli C, Scherz T, D'Ambrosio D, Linscheid P, Vaclavkova A, Pirozek-Lawniczek M, Kracker H, Sprenger T. Kappos L, et al. Among authors: havrdova ek. JAMA Neurol. 2021 May 1;78(5):558-567. doi: 10.1001/jamaneurol.2021.0405. JAMA Neurol. 2021. PMID: 33779698 Free PMC article. Clinical Trial.
Defining secondary progressive multiple sclerosis.
Lorscheider J, Buzzard K, Jokubaitis V, Spelman T, Havrdova E, Horakova D, Trojano M, Izquierdo G, Girard M, Duquette P, Prat A, Lugaresi A, Grand'Maison F, Grammond P, Hupperts R, Alroughani R, Sola P, Boz C, Pucci E, Lechner-Scott J, Bergamaschi R, Oreja-Guevara C, Iuliano G, Van Pesch V, Granella F, Ramo-Tello C, Spitaleri D, Petersen T, Slee M, Verheul F, Ampapa R, Amato MP, McCombe P, Vucic S, Sánchez Menoyo JL, Cristiano E, Barnett MH, Hodgkinson S, Olascoaga J, Saladino ML, Gray O, Shaw C, Moore F, Butzkueven H, Kalincik T; MSBase Study Group. Lorscheider J, et al. Among authors: havrdova e. Brain. 2016 Sep;139(Pt 9):2395-405. doi: 10.1093/brain/aww173. Epub 2016 Jul 7. Brain. 2016. PMID: 27401521
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.
Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O'Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS. Polman CH, et al. Among authors: havrdova e. Ann Neurol. 2011 Feb;69(2):292-302. doi: 10.1002/ana.22366. Ann Neurol. 2011. PMID: 21387374 Free PMC article.
ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis.
Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, Clanet M, Comi G, Derfuss T, Fazekas F, Hartung HP, Havrdova E, Hemmer B, Kappos L, Liblau R, Lubetzki C, Marcus E, Miller DH, Olsson T, Pilling S, Selmaj K, Siva A, Sorensen PS, Sormani MP, Thalheim C, Wiendl H, Zipp F. Montalban X, et al. Among authors: havrdova e. Eur J Neurol. 2018 Feb;25(2):215-237. doi: 10.1111/ene.13536. Epub 2018 Jan 19. Eur J Neurol. 2018. PMID: 29352526 Free article.
Update on the management of multiple sclerosis during the COVID-19 pandemic and post pandemic: An international consensus statement.
Reyes S, Cunningham AL, Kalincik T, Havrdová EK, Isobe N, Pakpoor J, Airas L, Bunyan RF, van der Walt A, Oh J, Mathews J, Mateen FJ, Giovannoni G. Reyes S, et al. Among authors: havrdova ek. J Neuroimmunol. 2021 Aug 15;357:577627. doi: 10.1016/j.jneuroim.2021.577627. Epub 2021 Jun 7. J Neuroimmunol. 2021. PMID: 34139567 Free PMC article. Review.
Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis.
Brown JWL, Coles A, Horakova D, Havrdova E, Izquierdo G, Prat A, Girard M, Duquette P, Trojano M, Lugaresi A, Bergamaschi R, Grammond P, Alroughani R, Hupperts R, McCombe P, Van Pesch V, Sola P, Ferraro D, Grand'Maison F, Terzi M, Lechner-Scott J, Flechter S, Slee M, Shaygannejad V, Pucci E, Granella F, Jokubaitis V, Willis M, Rice C, Scolding N, Wilkins A, Pearson OR, Ziemssen T, Hutchinson M, Harding K, Jones J, McGuigan C, Butzkueven H, Kalincik T, Robertson N; MSBase Study Group. Brown JWL, et al. Among authors: havrdova e. JAMA. 2019 Jan 15;321(2):175-187. doi: 10.1001/jama.2018.20588. JAMA. 2019. PMID: 30644981 Free PMC article.
Effects of High- and Low-Efficacy Therapy in Secondary Progressive Multiple Sclerosis.
Roos I, Leray E, Casey R, Horakova D, Havrdova E, Izquierdo G, Madueño SE, Patti F, Edan G, Debouverie M, Pelletier J, Ozakbas S, Amato MP, Clavelou P, Grammond P, Boz C, Buzzard K, Skibina O, Ciron J, Gerlach O, Grand'Maison F, Lechner-Scott J, Malpas C, Butzkueven H, Vukusic S, Kalincik T; MSBase and OFSEP Study Groups. Roos I, et al. Among authors: havrdova e. Neurology. 2021 Aug 31;97(9):e869-e880. doi: 10.1212/WNL.0000000000012354. Epub 2021 Jun 30. Neurology. 2021. PMID: 34193589
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.
Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW; AFFIRM Investigators. Polman CH, et al. Among authors: havrdova e. N Engl J Med. 2006 Mar 2;354(9):899-910. doi: 10.1056/NEJMoa044397. N Engl J Med. 2006. PMID: 16510744 Free article. Clinical Trial.
252 results